@article{fdi:010072491,
  title = {{O}utcomes of {HIV}-infected versus {HIV}-noninfected patients treated for drug-resistance tuberculosis : multicenter cohort study},
  author = {{B}astard, {M}. and {S}anchez-{P}adilla, {E}. and du {C}ros, {P}. and {K}hamraev, {A}. {K}. and {P}arpieva, {N}. and {T}illyashaykov, {M}. and {H}ayrapetyan, {A}. and {K}imenye, {K}. and {K}hurkhumal, {S}. and {D}lamini, {T}. and {P}erez, {S}. {F}. and {T}elnov, {A}. and {H}ewison, {C}. and {V}araine, {F}. and {B}onnet, {M}aryline},
  editor = {},
  language = {{ENG}},
  abstract = {{B}ackground {T}he emergence of resistance to anti-tuberculosis ({DR}-{TB}) drugs and the {HIV} epidemic represent a serious threat for reducing the global burden of {TB}. {A}lthough data on {HIV}-negative {DR}-{TB} treatment outcomes are well published, few data on {DR}-{TB} outcomes among {HIV} co-infected people is available despite the great public health importance. {M}ethods {W}e retrospectively reported and compared the {DR}-{TB} treatment outcomes of {HIV}-positive and {HIV}-negative patients treated with an individualized regimen based on {WHO} guidelines in seven countries: {A}bkhazia, {A}rmenia, {C}olombia, {K}enya, {K}yrgyzstan, {S}waziland and {U}zbekistan. {R}esults {O}f the 1,369 patients started {DRTB} treatment, 809 (59.1%) were multi-drug resistant ({MDR}-{TB}) and 418 (30.5%) were {HIV}-positive. {HIV}-positive patients were mainly from {A}frican countries (90.1%) while {HIV}-negative originated from {F}ormer {S}oviet {U}nion ({FSU}) countries. {D}espite a higher case fatality rate (19.0% vs 9.4%), {HIV}-positive {MDR}-{TB} patients had a 10% higher success rate than {HIV}-negative patients (64.0% vs 53.2%, p = 0.007). {N}o difference in treatment success was found among polydrug-resistant ({PDR}-{TB}) patients. {O}verall, lost to follow-up rate was much higher among {HIV}-negative (22.0% vs. 8.4%). {O}lder age and not receiving {ART} were the only factors associated with unfavorable treatment outcome among {HIV}-positive patients. {C}onclusions {A}s already known for {HIV}-negative patients, success rate of {DR}-{TB} {HIV}-positive patients remains low and requires more effective {DR}-{TB} regimen using new drugs also suitable to {HIV}-infected patients on {ART}. {T}he study also confirms the need of {ART} introduction in {HIV} co-infected patients.},
  keywords = {{ABKHAZIE}, {ARMENIE} ; {COLOMBIE} ; {KENYA} ; {KIRGHIZSTAN} ; {SWAZILAND} ; {OUZBEKISTAN}.},
  booktitle = {},
  journal = {{PL}o{S} {O}ne},
  volume = {13},
  numero = {3},
  pages = {e0193491 [14 p.]},
  ISSN = {1932-6203},
  year = {2018},
  DOI = {10.1371/journal.pone.0193491},
  URL = {https://www.documentation.ird.fr/hor/fdi:010072491},
}